#ESMO26 🚨 KEYNOTE-866: The final EFS analysis (N=907) of perioperative pembrolizumab + cisplatin/gemcitabine vs chemotherapy alone:

🔹 5-year EFS: 63.5% vs 61.9% (HR 0.88; p=0.137)
🔹 5-year OS: 70.8% vs 70.9% (HR 1.00)
🔹 pCR: 44.4% vs 35.8%
🔹 Grade 3–5 AEs: 80.2% vs 75.1%

Despite a numerically higher pCR rate, no significant EFS benefit emerged, and OS was virtually identical.

🚨In an evolving perioperative MIBC landscape, KEYNOTE-866 does not support adding pembrolizumab to cisplatin/gemcitabine.

@urotoday @myESMO